

Juno Therapeutics Inc - Strategic SWOT Analysis Review

https://marketpublishers.com/r/J0CDAD73C1EEN.html

Date: August 2018

Pages: 39

Price: US\$ 125.00 (Single User License)

ID: J0CDAD73C1EEN

Abstracts

Juno Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – GlobalData's summarization of the company's business strategy.

SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin's Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc Key Recent Developments

Jan 12,2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO

Jan 05,2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer Dec 20,2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership

Nov 27,2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor



to the CEO

Nov 01,2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.



Contents

SECTION 1 - ABOUT THE COMPANY

Juno Therapeutics Inc - Key Facts

Juno Therapeutics Inc - Key Employees

Juno Therapeutics Inc - Key Employee Biographies

Juno Therapeutics Inc - Major Products and Services

Juno Therapeutics Inc - History

Juno Therapeutics Inc - Company Statement

Juno Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 - COMPANY ANALYSIS

Company Overview

Juno Therapeutics Inc - Business Description

R&D Overview

Juno Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Juno Therapeutics Inc - Strengths

Juno Therapeutics Inc - Weaknesses

Juno Therapeutics Inc - Opportunities

Juno Therapeutics Inc - Threats

Juno Therapeutics Inc - Key Competitors

SECTION 3 - COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Juno Therapeutics Inc, Recent Deals Summary

SECTION 4 – COMPANY'S RECENT DEVELOPMENTS

Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General:



Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO

Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer Dec 20, 2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership

Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO

Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results Oct 12, 2017: Biomarkers May Help Identify Patients at Increased Risk of Neurotoxicity From CD19 CAR T-cell Therapy

Oct 11, 2017: New insights into CAR T-cell therapy's potential side effects
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics
Collaboration for Technical Progress Towards Overcoming the Tumor
Microenvironment

Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Juno Therapeutics Inc, Key Facts

Juno Therapeutics Inc, Key Employees

Juno Therapeutics Inc, Key Employee Biographies

Juno Therapeutics Inc, Major Products and Services

Juno Therapeutics Inc, History

Juno Therapeutics Inc, Subsidiaries

Juno Therapeutics Inc, Joint Venture

Juno Therapeutics Inc, Key Competitors

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD

2018

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD

2018

Juno Therapeutics Inc, Recent Deals Summary



List Of Figures

LIST OF FIGURES

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Tragara Pharmaceuticals Inc
Novartis Pharmaceuticals Corp
NeoGenomics Inc
ImmuneXcite Inc
Eiger BioPharmaceuticals Inc



I would like to order

Product name: Juno Therapeutics Inc - Strategic SWOT Analysis Review Product link: https://marketpublishers.com/r/J0CDAD73C1EEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/J0CDAD73C1EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970